World AIDS Day 2015: Paediatric HIV projects update from the teamWorld AIDS Day 2015: Paediatric HIV projects update from the team
World AIDS Day 2015: Paediatric HIV projects update from the teamAt the close of 2015, we would like to take this opportunity to update you on the status of DNDi’s paediatric HIV 4-in-1 formulation development programme.
Breakthrough treatments for the most neglected diseases: diversifying approaches is required to expand the development pipeline with new chemical entitiesBreakthrough treatments for the most neglected diseases: diversifying approaches is required to expand the development pipeline with new chemical entities
Breakthrough treatments for the most neglected diseases: diversifying approaches is required to expand the development pipeline with new chemical entitiesGraeme Bilbe, Research & Development Director, DNDi [November 2015] Addressing the lack of patient-adapted treatments for those suffering from neglected diseases is no easy task. DNDi’s initial short-term strategies were designed to quickly provide improved treatments through new formulations or combinations of existing drugs, and/or improved treatment regimens. Six new treatments have been delivered since 2003.
R&D status November 2015: DNDi Filarial diseases programmeR&D status November 2015: DNDi Filarial diseases programme
R&D status November 2015: DNDi Filarial diseases programme[November 2015] Filarial diseases are caused by parasitic worms of the helminth family. They include onchocerciasis (also known as River Blindness), lymphatic filariasis (also known as elephantiasis), and loiasis (also known as African eye-worm). The worms are transmitted by insect vectors to humans, mainly in Africa and Southeast Asia. About 168 million people are infected by the three diseases.
R&D status November 2015: DNDi Sleeping Sickness programmeR&D status November 2015: DNDi Sleeping Sickness programme
R&D status November 2015: DNDi Sleeping Sickness programme[November 2015] Human African trypanosomiasis (HAT), also known as ‘sleeping sickness’, is transmitted by the bite of a tsetse fly. While currently its prevalence is declining, 21 million people are still at risk across 36 Sub-Saharan Africa countries with most of the cases occurring in the Democratic Republic of Congo (89% of all cases in 2013).
- Clinical Research Malaysia and the Drugs for Neglected Diseases initiative Sign Agreement to Launch Clinical Studies for a Public Health Approach to Hepatitis C in Malaysia 13 January 2016
- DNDi Statement on KaloBios’ Intention to Raise Price of Chagas Drug and File for FDA Priority Review 14 December 2015
- World AIDS Day 2015: Study Begins in Kenya for Recently-Approved Paediatric HIV Treatment 30 November 2015
- Drugs for Neglected Diseases initiative Unveils New Plan for Neglected Patients at a key gathering of experts in India 16 October 2015
- French Development Agency AFD and DNDi sign partnership agreement for control of leishmaniasis in East Africa 8 October 2015
- The Wall Street Journal: “Martin Shkreli’s Failed Last Play for a Pharmaceutical Coup” 2 February 2016
- Voice of America: “Why Zika will be hard to stop” 2 February 2016
- New York Times: “Vaccine for Zika Virus may be years away, disease experts warn” 1 February 2016
- Radio France Internationale: “Maladies tropicales négligées” 29 January 2016
- EIN Newsdesk: “Pushing collaboration and financial incentives in the global fight against superbugs” 29 January 2016
- Designing a paediatric study for an antimalarial drug including prior information from adults by Petit C, Jullien V, Samson A, Guedj J, Kiechel JR, Zohar S, Comets E. Antimicrob Agents Chemother, December 2015
- Optimizing drugs to reach treatment targets for children and adolescents living with HIV by Penazzato P, Lee J, Capparelli E, Essajee S.M, Ford N, Ojoo A, Pascual F, Sugandhi N and Lallemant M. Journal of the International AIDS Society, December 2015
- Novel amino-pyrazole ureas with potent in vitro and in vivo antileishmanial activity by Mowbray C, Braillard S, Speed W, Glossop P, Whitlock G, Gibson K, Mills J, Brown A, Gardner JM, Cao Y, Hua W, Morgans G, Feijens P-B, Matheeussen A, Maes L. Journal of Medicinal Chemistry, November 2015
- Generalizing boundaries for triangular designs, and efficacy estimation at extended follow-ups by Allison A, Edwards T, Omollo R, Alves F, Magirr D, Alexander NDE. Trials, 2015
- Hit and lead criteria in drug discovery for infectious diseases of the developing world by Katsuno K, Burrows JN, Duncan K, Hooft van Huijsduijnen R, Kaneko T, Kita K, Mowbray CE, Schmatz D, Warner P, and Slingsby BT. Nature Reviews Drug Discovery, October 2015
- Health for Sale: Debate on Access to Medicines and Innovation
February 5, 2016
The Hague, Netherlands
During its Presidency of the Council of the European Union, the Government of the Netherlands has committed to improving affordable access to safe and effective medicines. But how can it create real and lasting change? Join public health experts and government representatives to debate these issues. The event is being coordinated by DNDi and other partners.
- ASTMH in Kenya February 9, 2016 Nairobi, Kenya The symposium will bring together experts from the government, non-governmental organizations, affected counties in Kenya, regional experts in Neglected Tropical Diseases (NTDs) and research institutions to discuss innovative ways of increasing access to treatments for neglected diseases once trials are successfully completed.
- CTDDR 2016
6th International Symposium on Current Trends in Drug Discovery and ResearchFebruary 25-28, 2016
Robert Don, Graeme Bilbe, and Suman Rijal and will be presenting in a session on infectious diseases.
- 17th International Congress on Infectious Diseases March 2-5, 2016 Hyderabad, India Suman Rijal, Director of DNDi Regional Office India, will be co-chairing a symposium on visceral leishmaniasis in South Asia, and Vishal Goyal, Clinical Manager, will be presenting.
- Geneva Health Forum 2016 April 19-21, 2016 Geneva, Switzerland Carolina Batista, Regional Medical Manager, and Andrea Marchiol, Coordinator for the Chagas Operational Projects, will be presenting on access to treatment for Chagas disease.